1
|
Tyagi A, Mishra A. Optimal Balance of Hydrophobic Content and Degree of Polymerization Results in a Potent Membrane-Targeting Antibacterial Polymer. ACS OMEGA 2021; 6:34724-34735. [PMID: 34963955 PMCID: PMC8697380 DOI: 10.1021/acsomega.1c05148] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Accepted: 12/01/2021] [Indexed: 05/09/2023]
Abstract
Globally, excessive use of antibiotics has drastically raised the resistance frequency of disease-causing microorganisms among humans, leading to a scarcity of efficient and biocompatible drugs. Antimicrobial polymers have emerged as a promising candidate to combat drug-resistance pathogens. Along with the amphiphilic balance, structural conformation and molecular weight (M n) play an indispensable role in the antimicrobial potency and cytotoxic activity of polymers. Here, we synthesize cationic and amphiphilic methacrylamide random copolymers using free-radical copolymerization. The mole fraction of the hydrophobic groups is kept constant at approximately 20%, while the molecular weight (average number of linked polymeric units) is varied and the antibacterial and cytotoxic activities are studied. The chemical composition of the copolymers is characterized by 1H NMR spectroscopy. We observe that the average number of linked units in a polymer chain (i.e., molecular weight) significantly affects the polymer activity and selectivity. The antibacterial efficacy against both of the examined bacteria, Escherichia coli and Staphylococcus aureus, increases with increasing molecular weight. The bactericidal activity of polymers is confirmed by live/dead cell viability assay. Polymers with high molecular weight display high antibacterial activity, yet are highly cytotoxic even at 1 × MIC. However, low-molecular-weight polymers are biocompatible while retaining antibacterial potency. Furthermore, no resistance acquisition is observed against the polymers in E. coli and S. aureus. A comprehensive analysis using confocal and scanning electron microscopy (SEM) techniques shows that the polymers target bacterial membranes, resulting in membrane permeabilization that leads to cell death.
Collapse
Affiliation(s)
- Anju Tyagi
- Department
of Chemistry, Indian Institute of Technology
Gandhinagar, Palaj, Gandhinagar, Gujarat 382355, India
| | - Abhijit Mishra
- Department
of Materials Engineering, Indian Institute
of Technology Gandhinagar, Palaj, Gandhinagar, Gujarat 382355, India
- . Tel: (+91-79) 2395 2422
| |
Collapse
|
2
|
Tyagi A, Mishra A. Methacrylamide based antibiotic polymers with no detectable bacterial resistance. SOFT MATTER 2021; 17:3404-3416. [PMID: 33645619 DOI: 10.1039/d0sm02176h] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
The growing number of multidrug-resistant pathogens is a major healthcare concern. In search of alternatives to antibiotics, synthetic mimics of antimicrobial peptides (SMAMPs) in the form of antimicrobial polymers have gained tremendous attention. Here, we report the synthesis of a set of 7 amphiphilic water-soluble cationic copolymers using aminopropyl methacrylamide and benzyl methacrylamide repeat units that show significant antibacterial activity. The antibacterial activity was evaluated using a broth microdilution assay against S. aureus and E. coli, while toxicity to mammalian cells was quantified by hemolysis assay with human red blood cells (RBCs). We find that the antibacterial activity and selectivity of the polymers depends on the mole fraction of aromatic benzyl units (fbenzyl) and the average molecular weight (Mn). Polymers with fbenzyl of 0.10 and 0.19, named AB-10 and AB-19 respectively, exhibited the highest antibacterial efficacy without inducing hemolysis and were chosen for further study. Liposome dye leakage study and observations from confocal and scanning electron microscopy indicate that the AB polymers killed bacterial cells primarily by disrupting the cytoplasmic membrane. No resistant mutants of E. coli and S. aureus were obtained with AB-19 in a 30 day serial passage study.
Collapse
Affiliation(s)
- Anju Tyagi
- Department of Chemistry, Indian Institute of Technology Gandhinagar, Palaj, Gandhinagar, Gujarat 382355, India
| | | |
Collapse
|
3
|
Herbert DA. Successful Oral Ciprofloxacin Therapy of Neisseria elongata Endocarditis. Ann Pharmacother 2014; 48:1529-30. [DOI: 10.1177/1060028014545355] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Objective: To report successful oral ciprofloxacin therapy for Neisseria elongata endocarditis. Case Summary: A patient with N elongata endocarditis refused parenteral therapy, but his infection completely resolved with 7 weeks of oral ciprofloxacin. Discussion: This patient’s refusal of parenteral therapy prompted the use of oral ciprofloxacin because it is well absorbed and was expected to be very active against his organism. His infection resolved and did not relapse. Although successful oral therapy has been reported for endocarditis caused by Staphylococcus aureus, primarily in injection drug users, completely oral therapy for other organisms has not been previously described. Conclusions: When parenteral therapy is not possible, oral administration of highly active, well-absorbed antibiotics may be effective for selected cases of endocarditis caused by susceptible organisms.
Collapse
Affiliation(s)
- David A. Herbert
- Kaiser Permanente Medical Center and University of California at Davis, Sacramento, CA, USA
| |
Collapse
|
4
|
Cunha B. The Evolution of Antibiotic Administration: From Hospital to Outpatient Intravenous Administration to Oral Antibiotic Therapy. J Chemother 2013; 21:199-204. [DOI: 10.1179/joc.2009.21.2.199] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
5
|
Abrutyn E, Cabell CH, Fowler VG, Hoen B, Miro JM, Mestres CA, Sexton DJ, Corey GR. Medical treatment of endocarditis. Curr Infect Dis Rep 2010; 9:271-82. [PMID: 17618546 DOI: 10.1007/s11908-007-0043-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
Infective endocarditis (IE) remains a serious and deadly disease. The incidence, which varies by gender and on the presence of predisposing factors, has not decreased, due in part to the aging population with more healthcare exposures and predisposing risk factors such as prosthetic heart valves and intracardiac devices. The most important aspects of treatment in IE hinge upon early diagnosis, microorganism identification with susceptibility testing, and early initiation of appropriate antibiotic therapy. In addition, echocardiographic imaging is critical for both diagnostic and prognostic purposes. Early evaluation for surgery should be considered. Once a therapeutic strategy is begun, careful attention to the clinical course is necessary to ensure appropriate response to therapy and to identify complications early.
Collapse
Affiliation(s)
- Elias Abrutyn
- Duke Clinical Research Institute, DUMC Box 2705, Durham, NC 27710, USA
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Mancino P, Ucciferri C, Falasca K, Pizzigallo E, Vecchiet J. Methicillin-resistant Staphylococcus epidermidis (MRSE) endocarditis treated with linezolid. ACTA ACUST UNITED AC 2009; 40:67-73. [PMID: 17852941 DOI: 10.1080/00365540701509915] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Linezolid is not yet recognized as a standard therapy for infective endocarditis but its use becomes a necessity when infection is due to multidrug-resistant microorganisms. This report describes 1 patient with endocarditis treated with linezolid and 45 similar cases from the medical literature.
Collapse
Affiliation(s)
- Paola Mancino
- Clinic of Infectious Diseases, Centre of Excellence on Ageing, University 'G. d'Annunzio' School of Medicine, Chieti-Pescara, Italy
| | | | | | | | | |
Collapse
|
7
|
Herrmann DJ, Peppard WJ, Ledeboer NA, Theesfeld ML, Weigelt JA, Buechel BJ. Linezolid for the treatment of drug-resistant infections. Expert Rev Anti Infect Ther 2009; 6:825-48. [PMID: 19053895 DOI: 10.1586/14787210.6.6.825] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Multidrug-resistant pathogens have become increasingly common in contemporary healthcare. Specific to Gram-positive pathogens, methicillin-resistant Staphylococcus aureus (MRSA) is of particular concern, as it has been associated with increased hospital length of stay, higher healthcare expenditures and poorer outcomes. To date, linezolid is the first and only oxazolidinone approved by the US FDA for the treatment of infections caused by Gram-positive pathogens, including MRSA. This article will serve as a comprehensive review of linezolid, including an overview of the current market and its in vitro activity, with an in-depth review of its pharmacokinetic and pharmacodynamic profile. Emphasis will be placed on clinical data for the drug, both on- and off-label. The article will conclude with a brief overview of linezolid's pharmacoeconomic implications and safety profile, followed by a commentary and 5-year prospective analysis remarking on the future of the antimicrobial field as it relates to MRSA.
Collapse
Affiliation(s)
- David J Herrmann
- Trauma/Surgical Critical Care Pharmacist, Froedtert Hospital, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA.
| | | | | | | | | | | |
Collapse
|
8
|
Olaechea Astigarraga PM, Garnacho Montero J, Grau Cerrato S, Rodríguez Colomo O, Palomar Martínez M, Zaragoza Crespo R, Muñoz García-Paredes P, Cerdá Cerdá E, Alvarez Lerma F. [Summary of the GEIPC-SEIMC and GTEI-SEMICYUC recommendations for the treatment of infections caused by gram positive cocci in critical patients]. FARMACIA HOSPITALARIA 2008; 31:353-69. [PMID: 18348666 DOI: 10.1016/s1130-6343(07)75407-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
OBJECTIVE In recent years there has been an increase in infections caused by gram-positive cocci in critical patients, together with a rapid development of resistance to the antibiotics which are normally used to treat them. The objective is to prepare an antibiotic treatment guide for the most common infections caused by gram positive cocci in critical patients. This guide will help in the decision-making process regarding the care of such patients. METHOD Experts from two scientific societies worked together to prepare a consensus document. They were members of the Study Group on Infections in Critical Patients (GEIPC), which is part of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), and the Infectious Diseases Working Group (GTEI), belonging to the Spanish Society of Intensive Care Medicine and Coronary Units (SEMICYUC). There was a systematic review of the literature published up to September 2006 regarding this type of infections and the antibiotic treatments marketed to that date. An evidence grading system was applied according to the strength of the recommendation (categories A, B or C) and the level of evidence (categories I, II or III). Recommendations were given if there was consensus among the experts from both societies. RESULTS The antibiotic regimens recommended for treating infections caused by gram-positive cocci were presented in the form of tables, showing the recommendation grade. Alternatives were given for allergic patients. The scientific basis supporting the aforementioned recommendations is explained within the text and the references upon which they are based are cited. CONCLUSIONS A summary of an evidence-based practical guide for the treatment of infections caused by gram-positive cocci in critical patients is presented.
Collapse
|
9
|
Astigarraga PMO, Montero JG, Cerrato SG, Colomo OR, Martínez MP, Crespo RZ, García-Paredes PM, Cerdá EC, Lerma FA. [GEIPC-SEIMC (Study Group for Infections in the Critically Ill Patient of the Spanish Society for Infectious Diseases and Clinical Microbiology) and GTEI-SEMICYUC ( Working Group on Infectious Diseases of the Spanish Society of Intensive Medicine, Critical Care, and Coronary Units) recommendations for antibiotic treatment of gram-positive cocci infections in the critical patient]. Enferm Infecc Microbiol Clin 2007; 25:446-66. [PMID: 17692213 DOI: 10.1157/13108709] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
In recent years, an increment of infections caused by gram-positive cocci has been documented in nosocomial and hospital-acquired-infections. In diverse countries, a rapid development of resistance to common antibiotics against gram-positive cocci has been observed. This situation is exceptional in Spain but our country might be affected in the near future. New antimicrobials active against these multi-drug resistant pathogens are nowadays available. It is essential to improve our current knowledge about pharmacokinetic properties of traditional and new antimicrobials to maximize its effectiveness and to minimize toxicity. These issues are even more important in critically ill patients because inadequate empirical therapy is associated with therapeutic failure and a poor outcome. Experts representing two scientific societies (Grupo de estudio de Infecciones en el Paciente Crítico de la SEIMC and Grupo de trabajo de Enfermedades Infecciosas de la SEMICYUC) have elaborated a consensus document based on the current scientific evidence to summarize recommendations for the treatment of serious infections caused by gram-positive cocci in critically ill patients.
Collapse
|
10
|
Olaechea Astigarraga PM, Garnacho Montero J, Grau Cerrato S, Rodríguez Colomo O, Palomar Martínez M, Zaragoza Crespo R, Muñoz García-Paredes P, Cerdá Cerdá E, Alvarez Lerma F. Recomendaciones GEIPC-SEIMC y GTEI-SEMICYUC para el tratamiento antibiótico de infecciones por cocos grampositivos en el paciente crítico. Med Intensiva 2007; 31:294-317. [PMID: 17663956 DOI: 10.1016/s0210-5691(07)74829-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
In recent years, an increment of infections caused by gram-positive cocci has been documented in nosocomial and hospital-acquired infections. In diverse countries, a rapid development of resistance to common antibiotics against gram-positive cocci has been observed. This situation is exceptional in Spain but our country might be affected in the near future. New antimicrobials active against these multi-drug resistant pathogens are nowadays available. It is essential to improve our current knowledge about pharmacokinetic properties of traditional and new antimicrobials to maximize its effectiveness and to minimize toxicity. These issues are even more important in critically ill patients because inadequate empirical therapy is associated with therapeutic failure and a poor outcome. Experts representing two scientific societies (Grupo de estudio de Infecciones en el Paciente Critico de la SEIMC and Grupo de trabajo de Enfermedades Infecciosas de la SEMICYUC) have elaborated a consensus document based on the current scientific evidence to summarize recommendations for the treatment of serious infections caused by gram-positive cocci in critically ill patients.
Collapse
Affiliation(s)
- P M Olaechea Astigarraga
- Servicio de Medicina Intensiva, Hospital de Galdakao, Bo. de Labeaga s/n, 48960 Galdakao, Vizcaya, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Mylona E, Fanourgiakis P, Vryonis E, Golfinopoulou S, Skoutelis A, Platsouka E, Chatzis N. Linezolid-based therapy in Staphylococcus epidermidis endocarditis. Int J Antimicrob Agents 2007; 29:597-8. [PMID: 17229555 DOI: 10.1016/j.ijantimicag.2006.09.021] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2006] [Revised: 09/27/2006] [Accepted: 09/29/2006] [Indexed: 11/15/2022]
|
12
|
Muñoz P, Rodríguez-Creixéms M, Moreno M, Marín M, Ramallo V, Bouza E. Linezolid therapy for infective endocarditis. Clin Microbiol Infect 2007; 13:211-215. [PMID: 17328738 DOI: 10.1111/j.1469-0691.2006.01585.x] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Linezolid is not yet recognised as a standard therapy for infective endocarditis. This report describes nine patients with endocarditis treated with linezolid and 33 similar cases from the medical literature. The majority of cases involved multiresistant strains, and the reasons for administering linezolid were refractory disease (60%), intolerance (28%), sequential therapy (12%) and a resistant pathogen (1%). Linezolid was administered for a mean of 37 days, with a successful outcome in 79% of cases. Reversible adverse effects were described in ten cases. The mean follow-up period was 8.5 months. Further data from randomised controlled clinical trials are needed to determine the efficacy and safety of linezolid for treating endocarditis.
Collapse
Affiliation(s)
- P Muñoz
- Department of Clinical Microbiology-Infectious Diseases, Madrid, Spain.
| | | | - M Moreno
- Department of Cardiology and Internal Medicine, Hospital General Universitario Gregorio Marañón, University of Madrid, Madrid, Spain
| | - M Marín
- Department of Clinical Microbiology-Infectious Diseases, Madrid, Spain
| | - V Ramallo
- Department of Cardiology and Internal Medicine, Hospital General Universitario Gregorio Marañón, University of Madrid, Madrid, Spain
| | - E Bouza
- Department of Clinical Microbiology-Infectious Diseases, Madrid, Spain
| |
Collapse
|
13
|
Nathani N, Iles P, Elliott TSJ. Successful treatment of MRSA native valve endocarditis with oral linezolid therapy: a case report. J Infect 2006; 51:e213-5. [PMID: 16291272 DOI: 10.1016/j.jinf.2005.02.016] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/05/2005] [Indexed: 10/25/2022]
Abstract
Staphylococcal endocarditis is potentially fatal and is now the most common cause of infective endocarditis with a mortality rate of 25-47% [Hecht SR, Berger M. Right-sided endocarditis in intravenous drug users: prognostic features in 102 episodes. Ann Intern Med 1992;117:560-6]. Its treatment requires maintenance of bactericidal level of antibiotics for prolonged periods to attain a culture-negative state. Although intravenous vancomycin is currently the drug of choice for methicillin resistant Staphylococcus aureus (MRSA) endocarditis, we present a case treated successfully with oral linezolid for 4 weeks due to a lack of venous access.
Collapse
Affiliation(s)
- N Nathani
- Critical Care Unit, Department of Critical Care, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, UK.
| | | | | |
Collapse
|
14
|
Abstract
Traditionally, antibiotics have been administered intravenously (IV) for serious systemic infections. As more potent oral antibiotics were introduced, and their pharmacokinetic aspects studied, orally administered antibiotics have been increasingly used for serious systemic infections. Antibiotics ideal for oral administration are those that have the appropriate spectrum, high degree of activity against the presumed or known pathogen, and have good bioavailability. Oral antibiotics with high bioavailability, that is > or = 90% absorbed, achieve serum/tissue concentrations comparable to IV administered antibiotics at the same dose. The popularity of "IV to PO switch therapy" is possible because of the availability of many potent oral antibiotics with high bioavailability. Initial IV therapy is appropriate in patients who are in shock/have impaired intestinal absorption, but after clinical defervescence, completion of therapy should be accomplished with oral antibiotics. As experience with "IV to PO switch therapy" has accumulated, confidence in oral antimicrobics for therapy of serious systemic infections has continued to increase. The trend in treating serious systemic infections entirely with oral antimicrobial therapy will continue, and is clearly the wave of the future.
Collapse
Affiliation(s)
- Burke A Cunha
- Infectious Disease Division, Winthrop-University Hospital, Mineola, NY 11501, USA
| |
Collapse
|
15
|
Wareham DW, Abbas H, Karcher AM, Das SS. Treatment of prosthetic valve infective endocarditis due to multi-resistant Gram-positive bacteria with linezolid. J Infect 2006; 52:300-4. [PMID: 16099052 DOI: 10.1016/j.jinf.2005.05.022] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2004] [Accepted: 05/25/2005] [Indexed: 11/17/2022]
Abstract
OBJECTIVES Clinical experience with linezolid in the treatment of infective endocarditis either alone or in combination with other agents is limited. We describe our experience in the treatment of two patients with IE due to multi-resistant Gram-positive bacteria. METHODS One patient with MRSE and one with VRE endocarditis were treated with regimens containing linezolid. The killing kinetics of linezolid in combination with gentamicin or vancomycin against isolates of Staphylococcus epidermidis and Enterococcus faecalis were analysed in vitro. RESULTS Clinical response and eradication of bacteraemia was achieved with linezolid therapy in both patients. Time-kill curve studies showed that linezolid was bacteriostatic against the MRSE and VRE isolates used. Combination with gentamicin or vancomycin did not produce synergy or antagonism but at best only marginal additive effect. CONCLUSIONS Although bacteriostatic, linezolid provides an important therapeutic option in IE due to multi-resistant Gram-positive pathogens. It challenges the conventional wisdom that bactericidal synergy is required for the effective treatment of most cases of IE due to Gram-positive organisms.
Collapse
Affiliation(s)
- D W Wareham
- Department of Medical Microbiology, Barts and The London NHS Trust, London E1 1BB, UK
| | | | | | | |
Collapse
|
16
|
Hill EE, Herijgers P, Herregods MC, Peetermans WE. Infective endocarditis treated with linezolid: case report and literature review. Eur J Clin Microbiol Infect Dis 2006; 25:202-4. [PMID: 16525776 DOI: 10.1007/s10096-006-0111-5] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- E E Hill
- Department of Internal Medicine, Infectious Diseases, University Hospital Gasthuisberg, Herestraat 49, 3000, Leuven, Belgium.
| | | | | | | |
Collapse
|
17
|
Manfredi R, Sabbatani S, Chiodo F. Severe staphylococcal knee arthritis responding favourably to linezolid, after glycopeptide-rifampicin failure: a case report and literature review. ACTA ACUST UNITED AC 2005; 37:513-7. [PMID: 16012016 DOI: 10.1080/00365540510036589] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
A puzzling case report of a septicaemic post-surgical staphylococcal knee arthritis which did not respond to long-term courses of associated rifampicin and teicoplanin or vancomycin, despite apparently favourable in vitro susceptibility assays, but which rapidly resolved after i.v. followed by oral administration of linezolid is presented, and discussed in the context of the most recent literature evidence. The lack of response to a 14-d-long course of glycopeptides does not find explanation from the in vitro minimum inhibitory concentrations (MIC90) of involved organisms, which showed full susceptibility of Staphylococcus aureus to vancomycin and teicoplanin, and sensitivity of an accompanying Staphylococcus epidermidis isolated from blood cultures to vancomycin and rifampicin, with borderline 'intermediate' values found for teicoplanin. Since neither bone involvement nor abscess formation was of concern, effective glycopeptide and rifampicin penetration into infectious tissue should have been assured. From a clinical viewpoint, the introduction of a 2-week i.v. linezolid followed by 1 further week of oral linezolid led to complete clinical and microbiological cure, and an unexpected functional success.
Collapse
Affiliation(s)
- Roberto Manfredi
- Department of Clinical and Experimental Medicine, Division of Infectious Diseases, University of Bologna Alma Mater Studiorum, S. Orsola-Malpighi Hospital, Bologna, Italy.
| | | | | |
Collapse
|
18
|
Grim SA, Rapp RP, Martin CA, Evans ME. Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2005; 25:253-64. [PMID: 15767239 DOI: 10.1592/phco.25.2.253.56956] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVE To review available data regarding the efficacy of trimethoprim-sulfamethoxazole (TMP-SMX) for the treatment of infections caused by methicillin-resistant Staphylococcus aureus (MRSA). DATA SOURCES A MEDLINE search was performed (January 1966-December 2003) using the search terms Staphylococcus aureus , sulfamethoxazole, trimethoprim, co-trimoxazole, and methicillin resistance. Abstracts from infectious diseases meetings also were reviewed. DATA SYNTHESIS The reported rate of TMP-SMX resistance in S. aureus is highly variable. From a mechanistic standpoint, TMP-SMX resistance among MRSA appears to be distinct from multidrug resistance, although some anecdotal reports suggest otherwise. Clonal outbreaks of MRSA resistant to TMP-SMX have been described; of these, the Brazilian clone has more often been resistant to TMP-SMX than the Iberian clone. Rates of TMP-SMX resistance are particularly high in institutions serving large numbers of patients infected by the human immunodeficiency virus, due to increased exposure for Pneumocystis prophylaxis. Limited studies and case reports have found TMP-SMX useful against infections caused by MRSA. CONCLUSIONS A large body of anecdotal data, but only one randomized clinical trial, indicates the effectiveness of TMP-SMX as a treatment for MRSA infections. Double-blind, randomized controlled trials are needed to compare the two available oral agents-TMP-SMX and linezolid-against MRSA.
Collapse
Affiliation(s)
- Shellee A Grim
- Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, USA.
| | | | | | | |
Collapse
|
19
|
Calza L, Manfredi R, Chiodo F. Infective endocarditis: a review of the best treatment options. Expert Opin Pharmacother 2005; 5:1899-916. [PMID: 15330728 DOI: 10.1517/14656566.5.9.1899] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Despite significant advances in antimicrobial therapy and an enhanced ability to diagnose and treat complications, infective endocarditis is still associated with substantial morbidity and mortality today, and its incidence has not decreased over the past decades. This apparent paradox may be explained by a progressive change in risk factors, leading to an evolution in its epidemiological and clinical features. In fact, new risk factors for endocarditis have emerged, such as intravenous drug abuse, diffusion of heart surgery procedures and prosthetic valve implantation, atherosclerotic valve disease in elderly patients, and nosocomial disease. Recently identified microorganisms (including Bartonella spp., Abiotrophia defectiva, and the HACEK group of bacteria [including Haemophilus spp., Actinobacillus spp., Cardiobacterium hominis, Eikenella corrodens and Kingella kingae]) are sometimes the cause of culture-negative endocarditis, and emerging resistant bacteria (such as methicillin- or vancomycin-resistant Staphylococci and vancomycin-resistant Enterococci) are becoming a new challenge for conventional antibiotic therapy. New therapeutic approaches need to be developed for the treatment of infective endocarditis caused by drug-resistant Gram-positive cocci, and some antimicrobial compounds recently introduced in clinical practice (such as streptogramins and oxazolidinones) may be an effective alternative, but further clinical studies are needed in order to confirm their effectiveness and safety. This review should help redefine the best therapeutic and preventive strategies against infective endocarditis.
Collapse
Affiliation(s)
- Leonardo Calza
- Department of Clinical and Experimental Medicine, Division of Infectious Diseases, Alma Mater Studiorum University of Bologna, S. Orsola Hospital, via G. Massarenti 11, I-40138 Bologna, Italy.
| | | | | |
Collapse
|